- The German Federal Joint Committee decided on future regulations that would govern the prescription of medical cannabis as a benefit of statutory health insurance
- Khiron Life Sciences Corp. (TSXV: KHRN) welcomes this affirmation regarding the future of medical cannabis in Germany as a treatment option reimbursed by statutory health insurance
- Germany is the largest and fastest growing medical cannabis market in Europe
- Khiron Life Sciences Corp. (KHRN) opened trading at $0.045 per share
Big things are happening in the medical cannabis space in Germany.
After five years of observational data collection, the German Federal Joint Committee (G-BA) finally decided on 16 March 2023, on future regulations that would govern the prescription of medical cannabis as a benefit of statutory health insurance.
Following several months of discussions and thoroughly analyzing the data, the G-BA passed regulations that ensure patient care with medical cannabis and coverage by statutory health insurance.
Khiron Life Sciences Corp. (TSXV: KHRN), a medical cannabis company with core operations in Latin America and Europe, welcomes this affirmation of the G-BA regarding the future of medical cannabis in Germany as a treatment option reimbursed by statutory health insurance (SHI).
The main task of the G-BA is to define the scope of health care and to decide which services are covered by the SHI.
Under the German regulations for medical cannabis:
- All doctors are authorized to prescribe. The more than 50.000 general practitioners provide a large part of patient care in Germany
- Authorization to patients granted before the new regulations continue to apply
- Only new initial medical cannabis prescriptions as well as fundamental changes in therapy require approval by health insurance funds. These may only be refused in justified exceptional cases
- Reimbursements apply for both dry-flower and extracted medical cannabis products
In Germany, Khiron sells its comprehensive product portfolio directly to pharmacies through its EU-GMP distribution centre Pharmadrug Production GmbH, acquired last year.
Franziska Katterbach, President of Khiron Europe, commented on this news.
“In recent months, there has been a lot of discussion in Germany about the future of medical cannabis – especially with regards to the reimbursement of dried flowers and extracts. This important debate was often overshadowed by the discussion about the legalisation of recreational cannabis. It is therefore even more important that patients’ access to reimbursed medical cannabis products, including our Khiron product portfolio, has been confirmed while the regulatory framework for recreational cannabis remains under discussion. This illustrates the outstanding importance of medical cannabis: Patients First!”
Germany is the largest and fastest growing medical cannabis market in Europe which Khiron directly supplies via its fully owned EU-GMP certified distributor, Pharmadrug Production GmbH, with its growing product portfolio.
Khiron Life Sciences Corp. (KHRN) opened trading at $0.045 per share.
For full disclaimer information, click here.